These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Making (anti-) sense out of huntingtin levels in Huntington disease. Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884 [TBL] [Abstract][Full Text] [Related]
12. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702 [TBL] [Abstract][Full Text] [Related]
13. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease. Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024 [TBL] [Abstract][Full Text] [Related]
14. VCP cooperates with UBXD1 to degrade mitochondrial outer membrane protein MCL1 in model of Huntington's disease. Guo X; Qi X Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):552-559. PubMed ID: 27913212 [TBL] [Abstract][Full Text] [Related]
15. Haplotype-based stratification of Huntington's disease. Chao MJ; Gillis T; Atwal RS; Mysore JS; Arjomand J; Harold D; Holmans P; Jones L; Orth M; Myers RH; Kwak S; Wheeler VC; MacDonald ME; Gusella JF; Lee JM Eur J Hum Genet; 2017 Nov; 25(11):1202-1209. PubMed ID: 28832564 [TBL] [Abstract][Full Text] [Related]
16. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model. van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347 [TBL] [Abstract][Full Text] [Related]
17. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331 [TBL] [Abstract][Full Text] [Related]
18. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979 [TBL] [Abstract][Full Text] [Related]
19. Differential expression of normal and mutant Huntington's disease gene alleles. Persichetti F; Carlee L; Faber PW; McNeil SM; Ambrose CM; Srinidhi J; Anderson M; Barnes GT; Gusella JF; MacDonald ME Neurobiol Dis; 1996; 3(3):183-90. PubMed ID: 8980018 [TBL] [Abstract][Full Text] [Related]
20. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models. Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]